Ahmad Agha
Cardiovascular Disease · Biloxi, MSNPI 1730520768
Payments from drug & device makers
Across 182 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$621
- Boston Scientific$383
- Abiomed$311
- E.r. Squibb & Sons, L.L.C.$249
- Abbott$237
- Merck$231
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,07098%
- Gifts$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 49 | $621 |
| Boston Scientific | 7 | $383 |
| Abiomed | 8 | $311 |
| E.r. Squibb & Sons, L.L.C. | 16 | $249 |
| Abbott | 5 | $237 |
| Merck | 10 | $231 |
| GSK | 6 | $215 |
| Medtronic | 2 | $208 |
| Pfizer | 12 | $205 |
| Shockwave Medical, Inc | 2 | $197 |
| Amgen | 10 | $175 |
| Baxter Healthcare | 5 | $155 |
| Johnson & Johnson | 8 | $128 |
| Chiesi USA, Inc. | 2 | $94 |
| Lexicon Pharmaceuticals, Inc. | 3 | $93 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $71 |
| Esperion Therapeutics, Inc. | 4 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Novo Nordisk | 2 | $45 |
| AstraZeneca(2 entities) | 2 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| Cardiovascular Systems Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Heartflow, Inc. | 1 | $27 |
| Atricure, Inc. | 1 | $26 |
| Imperative Care, Inc | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| W. L. Gore & Associates, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Itamar Medical Inc | 1 | $22 |
| Impulse Dynamics (USA) Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| Penumbra, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Silk Road Medical, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,145 in reported general payments places this provider in the 50th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 183 | $182,251 |
| XareltoRivaroxaban | 142 | $124,027 |
| EntrestoSacubitril/Valsartan | 109 | $105,671 |
| Repatha SureclickEvolocumab | 53 | $44,240 |
| BrilintaTicagrelor | 22 | $20,890 |
| Rosuvastatin Calcium | 307 | $3,325 |
| Potassium Chloride | 139 | $2,457 |
| ClopidogrelClopidogrel Bisulfate | 182 | $2,385 |
| Amiodarone Hcl | 141 | $2,343 |
| Metoprolol Succinate | 257 | $2,231 |
| Carvedilol | 275 | $1,757 |
| Irbesartan | 43 | $1,632 |
| Valsartan | 75 | $1,584 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 47 | $1,542 |
| Atorvastatin Calcium | 135 | $1,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $205 | $182,251183 claims |
| Johnson & JohnsonXarelto | $128 | $124,027142 claims |
| NovartisEntresto | $621 | $105,671109 claims |
| AstraZenecaBrilinta | $31 | $20,89022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Biloxi
- Paul MullenBiloxi$29K
- Antoine RizkBiloxi$28K
- Barry BertoletTupelo$6.4M
- Dharmesh PatelSouthaven$1.9M
- James HaysJackson$782K
- John EstessTupelo$416K
- Donny StokesJackson$277K
- Mahmoud ZayedPascagoula$103K
- Benjamin BlossomTupelo$91K
- James HaysJackson$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.